Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famitinib plus docetaxel in advanced non-squamous NSCLC
CTR20140851Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of famitinib in Non-small cell lung cancer (NS-NSCLC), sponsored by Hengrui Therapeutics. Started Dec 2014; status: active.
02
Drugs
famitinib
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on CTR20140851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140851.